Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q3LIE5

UPID:
ADPRM_HUMAN

ALTERNATIVE NAMES:
ADPRibase-Mn; CDP-choline phosphohydrolase

ALTERNATIVE UPACC:
Q3LIE5; A8K9B4; D3DTS4; Q9BVD4; Q9NRU8

BACKGROUND:
Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase, known alternatively as ADPRibase-Mn and CDP-choline phosphohydrolase, is pivotal in breaking down ADP-ribose and CDP-alcohols. This enzymatic activity is essential for regulating second messengers like ADP-ribose, thereby influencing TRPM2 channel activation and playing a role in the cellular defense against oxidative damage.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Manganese-dependent ADP-ribose/CDP-alcohol diphosphatase offers a promising avenue for developing novel therapeutic approaches aimed at enhancing immune cell signaling and protecting against oxidative stress.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.